The ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing — on track for its fourth straight day of gains — compared to the broader index which is down by 0.11%.

The point-of-care diagnostics tech company, Lumos (ASX:LDX), announced that it has completed all the development and verification requirements to support its regulatory submission for ViraDx.

ViraDx is a 15-minute three-in-one COVID-19 and flu rapid antigen test used by healthcare professionals.

Regulatory submissions will soon be underway in North America where ViraDx falls into a category that is prioritised for regulatory reviews.

Meanwhile, Exopharm (ASX:EX1) has been granted a US patent for its LEAP exosome purification technology.

The patent positions Exopharm as a global leader in the commercial production of exosomes needed to enable exosome-based medicines.


Lumos and Exopharm share prices today:



Other ASX health stocks news this morning

Smartphone-based respiratory disease specialist ResApp Health (ASX:RAP) has entered into a three year distribution agreement with New York-based Sanrai International.

The agreement covers countries in Africa, the Middle East, South and Central America, the Caribbean and South Asia – regions with a combined population of around 3 billion people.

ResAppDx uses machine learning technology to analyse signatures in cough sounds using a smartphone’s built-in microphone to detect respiratory disease.

The app has already obtained a CE mark in Europe, and TGA approval in Australia.

Cell therapeutics specialist Cynata (ASX:CYP) has commenced a Phase 1 clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU).

The trial aims to recruit 30 adult patients with DFU who will be randomly assigned to receive either CYP-006TK, or standard care of treatment.

CYP-006TK is a polymer-coated silicon wound dressing seeded with Cymerus mesenchymal stem cells (MSC), and is designed to facilitate topical application to the wound.

Dimerix (ASX:DXB) has been awarded further funding worth $100k from the Australian government’s Biomedical Translation Bridge program.

The funds will support the commercialisation of Dimerix’ lead candidate, DMX-200, to treat patients with COVID-19.

DMX-200 was earlier selected for inclusion in the global REMAP-CAP study for patients with respiratory diseases associated with the COVID-19 disease



Share prices today:



At Stockhead we tell it like it is. While Exopharm and Dimerix are Stockhead advertisers, they did not sponsor this article.